SG11202105079QA - Fusosome compositions for cns delivery - Google Patents
Fusosome compositions for cns deliveryInfo
- Publication number
- SG11202105079QA SG11202105079QA SG11202105079QA SG11202105079QA SG11202105079QA SG 11202105079Q A SG11202105079Q A SG 11202105079QA SG 11202105079Q A SG11202105079Q A SG 11202105079QA SG 11202105079Q A SG11202105079Q A SG 11202105079QA SG 11202105079Q A SG11202105079Q A SG 11202105079QA
- Authority
- SG
- Singapore
- Prior art keywords
- cns delivery
- fusosome compositions
- fusosome
- compositions
- cns
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862767358P | 2018-11-14 | 2018-11-14 | |
US201962900064P | 2019-09-13 | 2019-09-13 | |
PCT/US2019/061424 WO2020102499A2 (en) | 2018-11-14 | 2019-11-14 | Fusosome compositions for cns delivery |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202105079QA true SG11202105079QA (en) | 2021-06-29 |
Family
ID=68808599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202105079QA SG11202105079QA (en) | 2018-11-14 | 2019-11-14 | Fusosome compositions for cns delivery |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220008557A1 (en) |
EP (1) | EP3880179A2 (en) |
JP (1) | JP2022507454A (en) |
KR (1) | KR20210133948A (en) |
CN (1) | CN113613633A (en) |
AU (1) | AU2019378881A1 (en) |
CA (1) | CA3120082A1 (en) |
IL (1) | IL283179A (en) |
SG (1) | SG11202105079QA (en) |
WO (1) | WO2020102499A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
WO2018201160A1 (en) | 2017-04-28 | 2018-11-01 | Agrospheres, Inc. | Compositions and methods for enzyme immobilization |
US11649265B2 (en) | 2017-04-28 | 2023-05-16 | Agrospheres, Inc. | Compositions and methods for the encapsulation and scalable delivery of agrochemicals |
CA3073449A1 (en) | 2017-09-25 | 2019-03-28 | Agrospheres, Inc. | Compositions and methods for scalable production and delivery of biologicals |
EP4025698A1 (en) | 2019-09-03 | 2022-07-13 | Sana Biotechnology, Inc. | Cd24-associated particles and related methods and uses thereof |
IL296621A (en) * | 2020-03-31 | 2022-11-01 | Sana Biotechnology Inc | Targeted lipid particles and compositions and uses thereof |
AU2022206324A1 (en) | 2021-01-11 | 2023-07-20 | Sana Biotechnology, Inc. | Use of cd8-targeted viral vectors |
IL307544A (en) | 2021-04-08 | 2023-12-01 | Sana Biotechnology Inc | Cd8-specific antibody constructs and compositions thereof |
AU2022280957A1 (en) | 2021-05-28 | 2023-11-30 | Sana Biotechnology, Inc. | Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses |
TW202321457A (en) | 2021-08-04 | 2023-06-01 | 美商薩那生物科技公司 | Use of cd4-targeted viral vectors |
WO2023039242A2 (en) * | 2021-09-13 | 2023-03-16 | Achelois Biopharma, Inc. | Multivalent interferon particles compositions and methods of use |
TW202342498A (en) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | Modified paramyxoviridae fusion glycoproteins |
TW202342757A (en) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | Modified paramyxoviridae attachment glycoproteins |
WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
WO2024073093A2 (en) * | 2022-09-30 | 2024-04-04 | Vesigen, Inc. | Arrdc1-mediated microvesicle-based delivery of therapeutic agents to cells and tissues of the eye |
WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL78703A (en) | 1985-05-10 | 1993-02-21 | Benzon Alfred | Method of producing extracellular enzymes, the enzymes produced thereby and compositions containing them; a hybrid plasmid and a dna fragment comprising dna encoding the enzymes; a microorganism harbouring the plasmid; and a method for removing nucleic acids from biological materials |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
WO1999032646A1 (en) | 1997-12-22 | 1999-07-01 | Oxford Biomedica (Uk) Limited | Equine infectious anaemia virus (eiav) based |
CZ137399A3 (en) | 1996-10-17 | 1999-07-14 | Oxford Biomedica (Uk) Limited | Retroviral production system for producing replication defective vector particles |
AU9399498A (en) | 1997-09-18 | 1999-04-05 | Trustees Of The University Of Pennsylvania, The | Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery |
GB9720465D0 (en) | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
FR2777909B1 (en) | 1998-04-24 | 2002-08-02 | Pasteur Institut | USE OF TRIPLEX-STRUCTURED DNA SEQUENCES FOR THE TRANSFER OF NUCLEOTID SEQUENCES IN CELLS, RECOMBINANT VECTORS CONTAINING THESE TRIPLEX SEQUENCES |
GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
WO2002088346A2 (en) | 2001-05-01 | 2002-11-07 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
WO2003037260A2 (en) * | 2001-10-30 | 2003-05-08 | Biogen, Inc. | Methods and compositions for treating parkinson's disease |
US20040028687A1 (en) | 2002-01-15 | 2004-02-12 | Waelti Ernst Rudolf | Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues |
JP2005521398A (en) | 2002-03-27 | 2005-07-21 | ベイラー カレッジ オブ メディスン | A powerful oncolytic herpes simplex virus for cancer treatment |
ES2627445T3 (en) | 2002-05-01 | 2017-07-28 | Miltenyi Biotec Technology, Inc. | Lentivirus vector particles resistant to complement inactivation |
ATE494362T1 (en) | 2002-05-14 | 2011-01-15 | Merck Sharp & Dohme | METHOD FOR PURIFYING ADENOVIRUS |
CN100488491C (en) | 2002-11-21 | 2009-05-20 | 派维翁生物技术有限公司 | High-efficiency fused vesicles, methods of producing them, and pharmaceutical compositions containing same |
WO2006027202A1 (en) | 2004-09-06 | 2006-03-16 | Unite De Recherche En Biotherapie Et Oncologie (Rubio) | Generation of multiparent cell hybrids |
JP2008518630A (en) | 2004-11-08 | 2008-06-05 | イェール ユニバーシティ | Riboswitch, structure-based compound design by riboswitch, and method of using riboswitch and composition with riboswitch |
JP2008528485A (en) * | 2005-01-20 | 2008-07-31 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | Methods for delivering nucleic acids to peripheral neurons |
DK2002003T3 (en) | 2005-05-27 | 2016-03-21 | Ospedale San Raffaele Srl | Gene vector comprising miRNA |
WO2007099387A1 (en) | 2006-03-03 | 2007-09-07 | Mymetics Corporation | Virosome-like vesicles comprising gp41-derived antigens |
JP2012508233A (en) * | 2008-11-07 | 2012-04-05 | チルドレンズ ホスピタル メディカル センター | Saposin C for application to transmembrane drug delivery systems, and related protein and peptide fusogenicity |
US9050269B2 (en) | 2009-03-10 | 2015-06-09 | The Trustees Of The University Of Pennsylvania | Protection of virus particles from phagocytosis by expression of CD47 |
US8697439B2 (en) | 2009-11-13 | 2014-04-15 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Direct protein delivery with engineered microvesicles |
WO2012156839A2 (en) | 2011-05-19 | 2012-11-22 | Ospedale San Raffaele S.R.L. | New generation of splice-less lentiviral vectors for safer gene therapy applications |
CN104781789B (en) | 2012-12-20 | 2018-06-05 | 三菱电机株式会社 | Car-mounted device |
US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
GB201412494D0 (en) | 2014-07-14 | 2014-08-27 | Ospedale San Raffaele And Fond Telethon | Vector production |
US20170112773A1 (en) | 2015-10-23 | 2017-04-27 | Board Of Regents, The University Of Texas System | Plasma membrane vesicles comprising functional transmembrane proteins |
AU2017301881A1 (en) | 2016-07-29 | 2019-02-07 | Juno Therapeutics, Inc. | Methods for assessing the presence or absence of replication competent virus |
-
2019
- 2019-11-14 KR KR1020217018175A patent/KR20210133948A/en unknown
- 2019-11-14 CN CN201980088528.XA patent/CN113613633A/en active Pending
- 2019-11-14 EP EP19817064.9A patent/EP3880179A2/en active Pending
- 2019-11-14 WO PCT/US2019/061424 patent/WO2020102499A2/en unknown
- 2019-11-14 AU AU2019378881A patent/AU2019378881A1/en active Pending
- 2019-11-14 US US17/293,842 patent/US20220008557A1/en active Pending
- 2019-11-14 CA CA3120082A patent/CA3120082A1/en active Pending
- 2019-11-14 JP JP2021526394A patent/JP2022507454A/en active Pending
- 2019-11-14 SG SG11202105079QA patent/SG11202105079QA/en unknown
-
2021
- 2021-05-13 IL IL283179A patent/IL283179A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210133948A (en) | 2021-11-08 |
IL283179A (en) | 2021-06-30 |
WO2020102499A3 (en) | 2020-07-23 |
EP3880179A2 (en) | 2021-09-22 |
CN113613633A (en) | 2021-11-05 |
JP2022507454A (en) | 2022-01-18 |
AU2019378881A1 (en) | 2021-06-03 |
US20220008557A1 (en) | 2022-01-13 |
WO2020102499A2 (en) | 2020-05-22 |
CA3120082A1 (en) | 2020-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283179A (en) | Fusosome compositions for cns delivery | |
GB201811312D0 (en) | Compositions | |
GB2586745B (en) | Compositions | |
SG11202009259VA (en) | Compositions | |
GB201916960D0 (en) | Compositions | |
SG11202104306XA (en) | Compositions | |
SG11202108460VA (en) | Compositions | |
GB201804548D0 (en) | Pharmaceutical compositions | |
IL289125A (en) | Compositions | |
SG11202013227UA (en) | Esterquat compositions | |
GB201908396D0 (en) | Compositions | |
GB201803923D0 (en) | Compositions | |
GB201808571D0 (en) | Pharmaceutical compositions | |
IL285046A (en) | Anti-apicomplexan compositions | |
GB201919234D0 (en) | Compositions | |
SG11202105271PA (en) | Improved self-tanning compositions | |
GB2570649B (en) | Compositions | |
GB201819206D0 (en) | Novel compositions | |
GB201805676D0 (en) | Compositions | |
GB201808567D0 (en) | Pharmaceutical compositions | |
GB2585259B (en) | Aggregate compositions | |
ZA202005658B (en) | Compositions | |
PT3768284T (en) | Compositions | |
GB201820233D0 (en) | Compositions | |
GB201816834D0 (en) | Compositions |